

Synthesis of Thiosemicarbazones as Substrates for Xanthine Oxidase Enzyme Activity

S. BEYAZTAS^{1,*}, E. FINDIK², M. CEYLAN² and O. ARSLAN¹

¹Balikesir University, Science and Art Faculty, Department of Chemistry/Biochemistry Section, Balikesir, Turkey ²Gaziosmanpasa University, Science and Art Faculty, Department of Chemistry/Organic Chemistry Section, Tokat, Turkey

*Corresponding author: Fax: +90 266 6121215; Tel: +90 266 6121278; E-mail: beyaztas@balikesir.edu.tr

Received: 5 April 2014;	Accepted: 1 July 2014;	Published online: 30 September 2014;	AJC-16164

Thiosemicarbazones were synthesized from 7-arylbicyclo[3.2.0]hept-2-en-6-ones (**1a-d**) and thiosemicarbazide. The compounds were purified on a silica gel column chromatography. The thiosemicarbazone compounds were tested *in vitro* effect on xanthine oxidase (XO) purified from bovine milk. These compounds exhibited activator effects on xanthine oxidase enzyme activity at low concentration. We examined K_M and V_{max} values for thiosemicarbazone derivatives at different pH values. The derivatives showed better values of K_M , V_{max} and V_{max}/K_M than xanthine. Particularly, (Z)-1-((1R,5S,E)-7-(4-methylbenzylidene)bicyclo[3.2.0]hept-2-en-6-ylidene) thiosemicarbazide (4Mtc) was the most suitable substrate, due to the lowest K_M and the highest V_{max}/K_M values. K_M and V_{max}/K_M values were 1 ×10⁻⁴ M and 1.11 × 10⁶ min⁻¹, respectively. We proposed here a novel substrate for xanthine oxidase which can be used to assess the activity of this enzyme.

Keywords: Xanthine oxidase, in vitro Effect, Kinetic parameters, Substrate, Thiosemicarbazone derivatives.

INTRODUCTION

Xanthine oxidoreductase (XOR) is a 290 kDa molybdenum containing enzyme that has been studied extensively from a biochemical perspective for more than hundred years^{1,2}. The enzyme is synthesized as xanthine dehydrogenase (XD; EC 1.1.3.204), but can be readily converted to xanthine oxidase (XO; EC 1.2.3.22) by oxidation of sulfhydryl residues or by proteolysis³⁻⁵. Xanthine dehydrogenase utilizes NAD⁺ as an electron acceptor and xanthine oxidase utilizes O₂ as an electron acceptor⁶⁻⁸. Xanthine oxidase is situated at the end of catabolic reactions of the purine nucleotide metabolism in humans and a few other uricotelic species. Its major function is to catalyze the oxidation of hypoxanthine to xanthine and xanthine to uric acid⁴. Xanthine oxidase is widely distributed throughout various organs including the liver, gut, lung, kidney, heart and brain, as well as the plasma 9-14. Xanthine oxidase is considered to be a main source of oxidative stress and destructive free radicals in ischemia-reperfusion injury associated with heart attacks and stroke and in spinal cord injury, as well as being a destructive force in myocardial or renal hypoxia and infarctions16-18.

Xanthine oxidase catalyzes the hydroxylation of carbon atoms of a wide variety of substrates, including hypoxanthine and xanthine, which are the physiological substrates in many organisms^{12,13}. Purines such as hypoxanthine and xanthine are good substrates for xanthine oxidase^{2,15}. Its mechanism of action, which was very complex, had been extensively studied, in many instances with the use of non-physiological substrates¹¹.

In this study, we studied effect of new thiosemicarbazone derivatives on xanthine oxidase. These compounds and their metal complexes have a wide range of biological properties¹⁹. Because of this, a large number of organic and metal-organic compounds derived from thiosemicarbazone have been the subject of most structural and medicinal studies. Some of the detected biological activities of the thiosemicarbazones are antibacterial, antifungal, antiarthritic, antimalarial, antiamebic, antitumor, antiviral and anti-HIV²⁰. Thiosemicarbazone derivatives usually react as ligands for metal cations by bonding through the sulphur and the azomethinic nitrogen atoms^{21,22}. Therefore, the search for clinically useful thiosemicarbazone is a growing field of interest. In this study, we describe a containing thione group and study their properties as a substrate of xanthine oxidase purified from bovine milk.

EXPERIMENTAL

Melting points of the compounds were measured using Electrothermal 9100 apparatus. IR spectrums (KBr or liquid) were taken by a Jasco FT/IR-430 Infrared spectrophotometer. ¹H and ¹³C NMR spectra were recorded using a Brucker Avance III instrument using TMS (δ 0.00) for ¹H NMR and CDCl₃ (δ 77.0) for ¹³C NMR spectroscopy as internal reference standards J values were given in Hz. The multiplicities of the signals in the ¹H NMR spectra are abbreviated by s (singlet), d (doublet), t (triplet), q (quarted), m (multiplet), br (broad) and combinations thereof. Elemental analyses were obtained from a LECO CHNS 932 Elemental Analyzer.

Sepharose 4B, L-tyrosine, benzamidine, protein assay reagents and chemicals for electrophoresis were obtained from Sigma Chem. Co. All other chemicals used were of analytical grade and obtained from either Sigma or Merck.

General procedure for synthesis of compounds: A solution of starting compounds 7-arylbicyclo[3.2.0]hept-2-en-6-ones (**1a-d**) and thiosemicarbazide (1:1) in ethanol was refluxed for 3 h. After the removal of the ethanol (**Scheme-I**), the crude product was purified on a silica gel column chromatography eluting with ethyl acetate-hexane.



Scheme-I: Synthesis of thiosemicarbazone derivatives (Mtc, 4Mtc, Ctc and Btc)

(Z)-1-((1R,5S,E)-7-(4-Methoxybenzylidene)bicyclo-[3.2.0]hept-2-en-6-ylidene) thiosemicarbazide (Mtc): Yield, 80 %; yellowish solid m.p. 167-169 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 10.82$ (s, 1H, -NH), 8.13 (s, 1H, -NH₂), 7.65 (s, 1H, -NH₂), 7.43 (d, J = 8.8 Hz, 2H, A part of AB system), 6.95 (d, J = 8.8 Hz, 2H, B part of AB system), 6.68 (s, 1H), 5.95 (m, 1H, A part of AB system), 5.80 (m, 1H, B part of AB system), 4.21 (m, 1H, A part of AB system), 3.96 (m, 1H, B part of AB system), 3.75 (s, 3H, -OCH₃), 2.51 (m, 2H). ¹³C-NMR (100 MHz, CDCl₃): $\delta = 178.37$, 159.65, 154.92, 141.70, 132.96, 130.14 (2C), 129.04, 128.64, 119.48, 114.96 (2C), 55.63, 51.46, 46.87, 35.22. IR (KBr, v_{max} , cm⁻¹): 3459, 3340, 1600, 1587, 1506. Anal. Calcd. for C₁₆H₁₇N₃OS: C, 64.19; H, 5.72; N, 14.04; S, 10.71. Found: C, 64.36; H, 5.58; N, 14.24; S, 10.93.

(Z)-1-((1R,5S,E)-7-(4-Chlorobenzylidene)bicyclo-[3.2.0]hept-2-en-6-ylidene) thiosemicarbazide (Ctc): Yield, 87 %; yellowish solid m.p. 183-185 °C. ¹H NMR (400 MHz, CDCl₃): δ = 10.95 (s, 1H, -NH), 8.2 (s, 1H, -NH₂), 7.71 (s, 1H, -NH₂), 7.49 (d, *J* = 8.6 Hz, 2H, A part of AB system), 7.43 (d, *J* = 8.6 Hz, 2H, B part of AB system), 6.72 (s, 1H, olefinic), 5.94 (m, 1H, A part of AB system), 5.82 (m, 1H, B part of AB system), 4.26 (m, 1H, A part of AB system), 3.98 (m, 1H, B part of AB system), 2.55 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 154.01, 145.26, 134.87, 133.33, 132.84, 130.17 (2C), 129.45 (2C), 128.61, 118.22, 51.66, 47.03, 35.01. IR (KBr, v_{max}, cm⁻¹): 3448, 3255, 1583, 1508, 1452. Anal. Calcd. for C₁₅H₁₄ClN₃S: C, 59.30; H, 4.64; N, 13.83; S, 10.55. Found: C, 59.12; H, 4.56; N, 13.98; S, 10.78.

(Z)-1-((1R,5S,E)-7-(4-Methylbenzylidene)bicyclo-[3.2.0]hept-2-en-6-ylidene) thiosemicarbazide (4Mtc): Yield, 85 %, yellowish solid m.p. 174-176 °C. ¹H NMR (400 MHz, CDCl₃): δ = 10.86 (s, 1H, -NH), 8.16 (s, 1H, -NH₂), 7.68 (s, 1H, -NH₂), 7.37 (d, J = 7.2 Hz, 2H, A part of AB system), 7.17 (d, J = 7.2 Hz, 2H, B part of AB system), 6.70 (s, 1H, olefinic), 5.93 (m, 1H, A part of AB system), 5.75 (m, 1H, B part of AB system), 4.22 (m, 1H, A part of AB system), 3.97 (m, 1H, B part of AB system), 2.51 (m, 2H), 2.27 (s, 3H, -CH₃). ¹³C NMR (100 MHz, CDCl₃): $\delta = 178.47$, 159.90, 154.65, 143.28, 138.10, 133.21, 133.03, 130.04 (2C), 128.59 (2C), 119.67, 151.66, 46.93, 35.28, 21.38. IR (KBr, v_{max}, cm⁻¹): 3502, 3369, 1573, 1508, 1436. Anal. Calcd. for C₁₆H₁₇N₃S: C, 67.81; H, 6.05; N, 14.83; S, 11.31. Found: C, 67.97; H, 6.23; N, 14.99; S, 11.54.

(**Z**)-1-((1**R**,5**S**,**E**)-7-(**4**-**Bromobenzylidene**)**bicyclo**-[**3.2.0]hept-2-en-6-ylidene**) **thiosemicarbazide** (**Btc**): Yield, 80 %, yellowish solid m.p. 169-171 °C. ¹H NMR (400 MHz, CDCl₃): δ = 10.95 (s, 1H, -NH), 8.23 (s, 1H, -NH₂), 7.71 (s, 1H, -NH₂), 7.56 (d, *J* = 8.4 Hz, 2H, A part of AB system), 7.42 (d, *J* = 8.4 Hz, 2H, B part of AB system), 6.70 (s, 1H, olefinic), 5.93 (m, 1H, A part of AB system), 5.81 (m, 1H, B part of AB system), 4.25 (m, 1H, A part of AB system), 3.98 (m, 1H, B part of AB system), 2.61-2.49 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 178.64, 154.01, 145.38, 135.19, 133.34, 132.36 (2C), 130.44 (2C), 128.57, 121.52, 118.30, 51.96, 47.03, 35.36. IR (KBr, v_{max}, cm⁻¹): 3438, 3257, 1583, 1508, 1452. Anal. Calcd. for C₁₅H₁₄BrN₃S: C, 51.73; H, 4.05; N, 12.07; S, 9.21. Found: C, 51.62; H, 4.32; N, 12.27; S, 9.44.

Enzyme purification: Fresh bovine milk, without added preservative, was cooled down to 4 °C, overnight. EDTA and toluene were added to give final concentrations of 2 mM and 3 % (v/v), respectively. The milk was churned with a blender at top speed for 0.5 h at room temperature. This sample was brought to 38 % saturation by addition of solid ammonium sulphate²³. The suspension was centrifuged at 15000 rpm for 0.5 h and the precipitate formed was discarded. The supernatant was brought to 50 % saturation with solid ammonium sulphate. The precipitate formed was collected by centrifugation at 15000 rpm for 1 h and dissolved 0.1 M *tris*-HCl (pH = 7.6).

The pooled precipitate obtained from bovine milk by using ammonium sulphate precipitation was subjected to affinity chromatography. The sample prior to that was loaded onto the affinity column containing benzamidine.

Affinity column equilibrated in 0.1 M glycine/0.1 M NaCl (pH=9). The sample was applied to the affinity gel. The affinity gel was washed with 0.1 M glycine (pH=9). Xanthine oxidase, was eluted with 25 mM benzamidine in 0.1 M glycine/0.1 M NaCl (pH=9). Fractions of 1.5 mL were collected and their absorbance measured at 280 nm.

Activity measurements: Xanthine oxidase activity was determined at 37 °C by the modified method of Massey *et al.*²⁴. The conversion of xanthine uric acid was followed by monitoring the change in absorbance at 295 nm, using CARY 1E, UV-visible spectrophotometer ($\varepsilon_{292} = 9.5 \text{ mM}^{-1} \text{ cm}^{-1}$). The reaction mixture contained 50 mM *tris*-HCl (pH = 7.6) and 0.15 mM xanthine, at 37 °C. The assay was initiated by the addition of the enzyme. One unit of enzyme activity was defined as the amount of enzyme that converts one µmol of xanthine to uric acid per min under defined conditions²³.

in vitro Activation kinetic studies: For the activation studies of some thiosemicarbazone derivatives, different

concentration were added to the enzyme activity. Xanthine oxidase enzyme activity with thiosemicarbazone derivatives were assayed by following the oxidation of xanthine. Activity % values of xanthine oxidase for six different concentrations of thiosemicarbazone derivatives were determined by regression analysis using Microsoft Office 2000 Excel. Xanthine oxidase activity without thiosemicarbazone derivative was accepted as 100 % active. The graphs exhibited the new thiosemicarbazone derivatives which were activator effect on the enzyme.

In addition, K_M and V_{max} values of the enzyme were determined on xanthine oxidase activity using different pH values. In order to achieve this, new thiosemicarbazone derivatives as a substrate were measured at different substrate concentrations at 37 °C. K_M and V_{max} values were determined by means of Lineweaver-Burke graphs.

Determination of total protein: The absorbance at 280 nm was used to monitor the protein in the column effluents. Quantitative protein determination was achieved by absorbance measurements at 595 nm according to Bradford method²⁵ with bovine serum albumin using as a standard.

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis: Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis was performed after having a purified enzyme. It was carried out in 10 and 3 % acrylamide-bisacrylamide concentration for the running and stacking gel, respectively, containing 0.1 % SDS according to Laemmli method²⁶. Sample was applied to the electrophoresis medium. Gel was stained overnight in 0.1 % Coomassie Brilliant Blue R-250 in 50 % methanol and 10 % acetic acid, then destained by frequently changing the same solvent, without using dye. The electrophoretic pattern was photographed with the system of produce as an image of the gel (Fig. 1).



Fig. 1. SDS-PAGE pattern of xanthine oxidase. The poled fractions from affinity chromatography was analyzed by SDS-PAGE (12 % and 3 %) and revealed by Coomassie Blue staining. Experimental conditions were as described in the method. Lane 1 contained 5 μ L of various molecular mass standards: 3-galactosidase, (116.0), bovine serum albumin (66.2), ovalbumin (45), lactate dehydrogenase, (35.0), Restriction endonuclease (25), 3-lactoglobulin (18.4), lysozyme (14.4)

RESULTS AND DISCUSSION

Xanthine oxidase is also plentiful in milk, which has made it a popular enzyme for study since it is easy to isolate and purify^{13,27-30}. Xanthine oxidase, a cellular redox enzyme, is highly expressed in mammary epithelial cells³⁰ but xanthine oxidase was extracted from fresh bovine milk without added preservative using toluene and EDTA in this study. Toluene together with the gradual increase in temperature (from 4 to 45 °C) during churning caused an efficient extraction of the enzyme from lipid micelles. Filtration of the churned milk through filtration paper could be fractionated directly with ammonium sulphate. The entire enzyme was successfully collected in a narrow range of ammonium sulphate concentration. At this step, a 35-fold purification was achieved³⁰⁻³². The precipitate form was collected and dissolved. The affinity gel was equilibrated and the dissolved sample prior to that was loaded onto an affinity column containing benzamidine. Gel was washed and xanthine oxidase was eluted. Fractions were collected and their absorbance measured at 280 nm.

Firstly, we examined the *in vitro* effects of original thiosemicarbazone derivatives (Fig. 2). The starting thiosemicarbazone derivatives **1a-d** (**Scheme-I**.) were first of all synthesized by the condensation of *cis*-bicyclo[3.2.0]hept-2-en-6one with corresponding aldehydes according to the recently published procedure³³. Then thiosemicarbazide was added to compounds **1a-d** in ethanol under the reflux conditions which gave the thiosemicarbazone derivatives (Mtc, 4Mtc, Ctc and Btc) in good yields (**Scheme-I**).



Fig. 2. Effect of Mtc, 4Mtc, Ctc and Btc on xanthine oxidase enzyme activity. Effect of Mtc, 4Mtc, Ctc and Btc on the enzyme activity of a purified xanthine oxidase from milk was assayed for enzyme activity in the presence of various concentrations of above thiosemicarbazone derivatives. The experimental conditions were 50 mM *tris*-HCl (pH = 7.6), 0.15 mM xanthine and 37 °C, constant concentration of enzyme. The five spectrophotometric measurement were made every 30 second by CARY 1E, UV-visible spectrophotometer ($\lambda_{292} = 9.5 \text{ mM}^{-1} \text{ cm}^{-1}$) at a wavelength of 295 nm

Xanthine and hypoxanthine³⁴ as substrate are commonly used to measure activity in xanthine oxidase¹¹. Fig. 2 showed the original thiosemicarbazone derivatives behaviour which raised the xanthine oxidase enzyme activity. Because of this ability of the compounds, we studied these compounds to discover whether the original compounds were used as a substrate or not. K_M and V_{max} values of the enzyme were determined on xanthine oxidase activity using different pH values. In order to obtain these results, the thiosemicarbazone derivatives as a substrate were measured at different substrate concentrations at 37 °C. K_M and V_{max} values were determined by means of Lineweaver-Burk graphs (Fig. 3, Table-3). K_M and V_{max} values for these compounds weren't determinated using *tris*-HCl (pH = 5) and *tris*-base (pH = 9) buffers. Because, this value is not meaningful with each other. K_M and V_{max} values of the enzyme were determined xanthine oxidase activity using *tris*-HCl (pH = 7.6) and different xanthine concentrations at 37 °C.

The K_M and V_{max} were determined using xanthine by Lineweaver-Burke graphs, 1.7×10^{-4} M and 0.58 EU/mL/min, respectively (Table-1). V_{max} was determined for Mtc, 4Mtc and Ctc 1 × 10⁻³ U/mL/min, 5.95 × 10⁻³ EU/mL/min, 0.32 × 10⁻³ EU/mL/min using *tris*-HCl (pH = 6). K_M values were found 2.01× 10⁻⁴ M., 2 × 10⁻³ and 9.03 × 10⁻⁵ M with the same buffer, respectively. According to the results, K_M and V_{max} values didn't give a meaningful value using *tris*-HCl (pH = 6) buffer for Btc (Table-1). K_M and V_{max} values were also seen in Table-1 for Mtc, 4Mtc, Btc and Ctc using *tris*-HCl (pH = 7) and *tris*-Base (pH = 8) buffers. *tris*-HCl (pH = 8) is the best buffer for having a highest enzyme activity due to the lowest K_M and the biggest V_{max} values for all the thiosemicarbazones (Table-1). For xanthine oxidase, all reactions were conducted at the optimal pH 8, too. In another study, the relative V_{max} values for hypoxanthine, xanthine and 6-thioxanthine were similar, as were their K_M values¹¹.





Fig. 3. K_M and V_{max} values of original thiosemicarbazone derivatives for xanthine oxidase. (a) Ctc. The experimental conditions were 50 mM *tris*-HCl (pH = 7.6) and 0.15 mM new thiosemicarbazone derivatives (Btc, Mtc, 4Mtc and Ctc) 0.1 M *tris*-HCl buffer (pH 7.6), 37 °C, constant concentration of enzyme. The five spectro-photometric measurement were made every 30 second by CARY 1E, UV-visible Spectrophotometer (λ_{292} = 9.5 mM⁻¹ cm⁻¹) at a wavelength of 295 nm. K_M and V_{max} graphics using new thiosemicarbazone derivatives were (a) Ctc, (b) Mtc, (c) 4Mtc and (d) Btc

Vol. 26, No. 21 (2014)

TABLE-2 VALUES OF KM AND Vmm USING ORIGINAL THIOSEMICARBAZONE DERIVATIVES							
V _{max} (EU/mL/min)	Mtc	4Mtc	Btc	Ctc			
pH = 6 tris-HCl	1×10^{-3}	5.95×10^{-3}	Not found meaningful value	0.32×10^{-3}			
pH = 7 tris-HCl	0.819	5.32×10^{-3}	2×10^{-3}	1.28×10^{-3}			
pH = 8 tris-Base	277.78	111.11	384.61	0.57			
		$K_{M}\left(M ight)$					
pH = 6 tris-HCl	2.01×10^{-4}	2×10^{-3}	Not found meaningful value	9.03×10^{-5}			
pH = 7 tris-HCl	2.32×10^{-4}	3.22×10^{-3}	3.95×10^{-4}	1.79×10^{-3}			
pH = 8 <i>tris</i> -Base	5×10^{-4}	1×10^{-4}	1×10^{-3}	1.063×10^{-4}			

VALUES OF V _{max} /K _M USING ORIGINAL THIOSEMICARBAZONE DERIVATIVES						
V _{max} /KM (EU/mL M)	Mtc	4Mtc	Btc	Ctc		
pH = 6 tris-HCl	4.97	2.97	-	33.54		
pH = 7 tris-HCl	353.02	1.65	5.06	0.71		
pH = 8 tris-Base	55.56×10^4	11.11×10^{5}	38.46×10^4	5362.18		

Especially, the compounds were more suitable substrate according to using xanthine as a substrate with using *tris*-base (pH = 8) buffer (Tables 1 and 2) But mostly in some studies xanthine is commonly used as a substrate to measure activity in xanthine oxidase³⁰. Particularly, 4Mtc was the most suitable substrate, due to the lowest K_M and the biggest V_{max}/K_M values, followed by xanthine, Mtc, Ctc and Btc (Tables 1 and 2).

The thiosemicarbazones using as a substrate had better values of K_M , V_{max} and V_{max}/K_M comparing with xanthine. So here in this study the results were given the new thiosemicarbazones could be candidates as substrates in order to measure xanthine oxidase activity. *tris*-Base (pH = 8) was the best buffer for measurement of xanthine oxidase enzyme activity for the new derivatives which the data's were also seen in Tables 1 and 2. Among the compounds, 4Mtc was the most suitable substrate. Also xanthine was given better results using pH 8 buffers (Tables 1 and 2).

Conclusion

In humans, xanthine oxidase is normally found in the liver and not free in the blood. During severe liver damage, xanthine oxidase is released into the blood, so a blood assay for xanthine oxidase is a way to determine if liver damage has happened. So its regulation is also so important such as the lack of xanthine oxidase leads to high concentration of xanthine in blood and can cause health problems, for this purpose in this study we proposed novel substrates for xanthine oxidase which could be used to assess the activity of this enzyme regulation.

ACKNOWLEDGEMENTS

This work has been supported by Balikesir University Research Project (2009/17) and carried out at the Balikesir University Research Center of Applied Sciences (BURCAS).

REFERENCES

- J.L. McManaman, M.C. Neville and R.M. Wright, Arch. Biochem. Biophys., 371, 308 (1999).
- V. Massey, H. Komai, G. Palmer and G.B. Elion, J. Biol. Chem., 245, 2837 (1970).
- 3. R. Harrison, Free Radic. Biol. Med., 33, 774 (2002).
- 4. R. Harrison, Int. Dairy J., 16, 546 (2006).

- 5. N. Silanikove, F. Shapiro and G. Leitner, *Biochem. Biophys. Res. Commun.*, **363**, 561 (2007).
- C. Galbusera, P. Orth, D. Fedida and T. Spector, *Biochem. Pharmacol.*, 71, 1747 (2006).
- 7. J.M. Pauff and R. Hille, J. Nat. Prod., 72, 725 (2009).
- 8. R. Hille, Eur. J. Inorg. Chem., 2006, 1913 (2006).
- K.R. Sathisha, S.A. Khanum, J.N.N.S. Chandra, F. Ayisha, S. Balaji, G.K. Marathe, S. Gopal and K.S. Rangappa, *Bioorg. Med. Chem.*, 19, 211 (2011).
- M.G. Bonini, S. Miyamoto, P.D. Mascio and O. Augusto, J. Chem. Biol., 279, 51836 (2004).
- E. Kulikowska, B. Kierdaszuk and D. Shugar, *Acta Biochim. Pol.*, 51, 493 (2004).
- K. Okamoto, Y. Kawaguchi, B.T. Eger, E.F. Pai and T. Nishino, J. Am. Chem. Soc., 132, 17080 (2010).
- 13. T. Nishino, K. Okamoto, B.T. Eger, E.F. Pai and T. Nishino, *FEBS J.*, **275**, 3278 (2008).
- Z.L. You, D.H. Shi, C. Xu, Q. Zhang and H.L. Zhu, *Eur. J. Med. Chem.*, 43, 862 (2008).
- J.H. Kim, J.A. Odutola, J. Popham, L. Jones and S. von Laven, *J. Inorg. Biochem.*, 84, 145 (2001).
- J. George and A. Struthers, J. Therap. Clinic Risk Manage., 5, 799 (2009).
- 17. D.M. Yellon and D. Hausenloy, J. N. Engl. J. Med., 357, 1121 (2007).
- 18. C. Li and R.M. Jackson, Am. J. Physiol. Cell Physiol., 282, 227 (2002).
- 19. Pal, F. Basuli and S. Bhattacharya, J. Chem. Sci., 114, 255 (2002).
- I. Kizilcikli, Y.D. Kurt, B. Akkurt, A.Y. Genel, S. Birteksöz, G. Ötük and B. Ülküseven, *Folia Microbiol. (Praha)*, **52**, 15 (2007).
- M.C. Rodriguez-Arguelles, M.B. Ferrari, G.G. Fava, C. Pelizzi, G. Pelosi, R. Albertini, A. Bonati, P.P. Dall'Aglio, P. Lunghi and S. Pinelli, *J. Inorg. Biochem.*, 66, 7 (1997).
- J. Perez, A. Matesanz, A. Martinambite, P. Navarro, C. Alonso and P. Souza, J. Inorg. Biochem., 75, 255 (1999).
- N. Özer, M. Müftüoglu, D. Ataman, A. Ercan and I.H. Ögüs, J. Biochem. Biophys., 39, 153 (1999).
- 24. V. Massey, P.E. Brumby and H. Komai, J. Biol. Chem., 244, 1682 (1969).
- 25. M.M. Bradford, Anal. Biochem., 72, 248 (1976).
- 26. U.K. Laemmli, Nature, 227, 680 (1970).
- 27. R. Harrison, Drug Metab. Rev., 36, 363 (2004).
- M.A. Hediger, R.J. Johnson, H. Miyazaki and H. Endou, *Physiology* (*Bethesda*), 20, 125 (2005).
- 29. R. Hille, Arch. Biochem. Biophys., 433, 107 (2005).
- C.R. Stevens, T.M. Millar, J.G. Clinch, J.M. Kanczler, T. Bodamyali and D.R. Blake, *Lancet*, 356, 829 (2000).
- A. Bytyqi-Damoni, H. Genç, M. Zengin, S. Beyaztas, N. Gençer and O. Arslan, Art. Cells Blood Subst. Biotech., 40, 369 (2012).
- 32. S. Beyaztas and O. Arslan, J. Biol. Chem., 39, 195 (2011).
- 33. M. Ceylan and E. Findik, Synth. Commun., 39, 1046 (2009).
- 34. R. Hile and T. Nishino, FASEB J., 9, 995 (1995).